Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

Benzinga Newsdesk www.benzinga.com Positive 83.3%

Neg 0% Neu 0% Pos 83.3%

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy and announces $75 price target.